Auxano Advisors LLC Takes Position in Zoetis Inc. $ZTS

Auxano Advisors LLC acquired a new stake in Zoetis Inc. (NYSE:ZTS) in the 2nd quarter, Holdings Channel.com reports. The institutional investor acquired 1,587 shares of the company’s stock, valued at approximately $247,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ZTS. Prudential PLC raised its holdings in shares of Zoetis by 1.7% in the 2nd quarter. Prudential PLC now owns 168,150 shares of the company’s stock valued at $26,223,000 after purchasing an additional 2,886 shares in the last quarter. Cumberland Partners Ltd increased its holdings in Zoetis by 500.0% during the second quarter. Cumberland Partners Ltd now owns 18,000 shares of the company’s stock valued at $2,807,000 after buying an additional 15,000 shares during the period. Hikari Tsushin Inc. purchased a new position in Zoetis during the second quarter valued at approximately $1,176,000. Dynamic Technology Lab Private Ltd raised its stake in Zoetis by 537.3% in the second quarter. Dynamic Technology Lab Private Ltd now owns 11,650 shares of the company’s stock worth $1,817,000 after buying an additional 9,822 shares in the last quarter. Finally, Howe & Rusling Inc. lifted its holdings in Zoetis by 9.4% during the second quarter. Howe & Rusling Inc. now owns 2,382 shares of the company’s stock worth $371,000 after buying an additional 205 shares during the period. 92.80% of the stock is currently owned by institutional investors.

Zoetis Price Performance

Shares of NYSE ZTS opened at $116.96 on Thursday. Zoetis Inc. has a fifty-two week low of $115.25 and a fifty-two week high of $181.85. The company has a market cap of $51.54 billion, a PE ratio of 20.13, a P/E/G ratio of 2.31 and a beta of 0.90. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. The business has a 50-day simple moving average of $138.98 and a two-hundred day simple moving average of $150.66.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, beating the consensus estimate of $1.62 by $0.08. The firm had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.42 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. Zoetis’s revenue was up .5% on a year-over-year basis. During the same period last year, the firm posted $1.58 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be paid a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.7%. The ex-dividend date is Friday, October 31st. Zoetis’s payout ratio is presently 33.67%.

Wall Street Analyst Weigh In

ZTS has been the topic of a number of analyst reports. Stifel Nicolaus cut their price target on Zoetis from $140.00 to $130.00 and set a “hold” rating on the stock in a report on Tuesday. JPMorgan Chase & Co. cut their target price on Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 5th. Weiss Ratings reissued a “hold (c-)” rating on shares of Zoetis in a research report on Wednesday, October 8th. BTIG Research lowered their price target on shares of Zoetis from $200.00 to $160.00 and set a “buy” rating on the stock in a report on Wednesday, November 12th. Finally, Argus reiterated a “buy” rating and set a $190.00 price objective on shares of Zoetis in a research note on Tuesday, September 9th. Six investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $178.89.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.